# A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer

> **NCT07527026** · PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT07527026
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527026, "A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07527026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*